niacinamide has been researched along with Granulocytic Leukemia, Chronic, Stable Phase in 3 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Javidi-Sharifi, N | 1 |
| Hobbs, G | 1 |
| Yeung, DT | 1 |
| Shanmuganathan, N | 1 |
| Hughes, TP | 2 |
| Réa, D | 1 |
| Mauro, MJ | 1 |
| Boquimpani, C | 1 |
| Minami, Y | 1 |
| Lomaia, E | 1 |
| Voloshin, S | 1 |
| Turkina, A | 1 |
| Kim, DW | 1 |
| Apperley, JF | 1 |
| Abdo, A | 1 |
| Fogliatto, LM | 1 |
| Kim, DDH | 1 |
| le Coutre, P | 1 |
| Saussele, S | 1 |
| Annunziata, M | 1 |
| Chaudhri, N | 1 |
| Sasaki, K | 1 |
| Chee, L | 1 |
| García-Gutiérrez, V | 1 |
| Cortes, JE | 1 |
| Aimone, P | 1 |
| Allepuz, A | 1 |
| Quenet, S | 1 |
| Bédoucha, V | 1 |
| Hochhaus, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors[NCT03106779] | Phase 3 | 233 participants (Actual) | Interventional | 2017-10-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by IS as measured by RQ-PCR. (NCT03106779)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asciminib | 40 |
| Bosutinib | 10 |
1 review available for niacinamide and Granulocytic Leukemia, Chronic, Stable Phase
| Article | Year |
|---|---|
Future Directions in Chronic Phase CML Treatment.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Discovery; Humans; Immun | 2021 |
1 trial available for niacinamide and Granulocytic Leukemia, Chronic, Stable Phase
| Article | Year |
|---|---|
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Female; Humans; Leukemia, | 2021 |
1 other study available for niacinamide and Granulocytic Leukemia, Chronic, Stable Phase
| Article | Year |
|---|---|
Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelog | 2022 |